Uric acid and cardiovascular risk.

By L. Hebert, B. Rovin. New England Journal of Medicine, 2009

1,309 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/367a7a98f181ace36d79733b5f35e1ea0c7303e6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Uric acid and chronic kidney disease: which is chasing which? (2013, background): “The role of uric acid in these conditions is discussed elsewhere [21, 22].”
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (2017, background): “Serum uric acid has been associated with an increased risk of CV death (33), but evidence is limited regarding the CV benefits of reducing uric acid (34), especially within the normal range and/or to the small degree observed in the EMPA-REG OUTCOME trial.”
Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. (2010, methodology): “before screening; and (3) stable renal function (baseline serum creati-”
The NALP3/NLRP3 Inflammasome Instigates Obesity-Induced Autoinflammation and Insulin Resistance (2011, background): “Furthermore, visceral adiposity and obesity are associated with an increase in monosodium urate (MSU) levels and increased risk of diabetes and atherosclerosi”
Glucose transporters in the 21st Century. (2010, background): “This mouse model should help test whether elevated plasma uric acid levels may lead to insulin resistance, hypertension, or atherosclerosis, as suggested by epidemiological studies (12).”
Uric Acid Induces Hepatic Steatosis by Generation of Mitochondrial Oxidative Stress (2012, background): “These studies are reawakening the possibility that uric acid may have a causal role in metabolic syndrome and cardiovascular disease (51).”